

Anti-TNFSF2/TNF α Antibody (Infliximab)

Introduction

Infliximab (Avakine) is a chimeric monoclonal IgG1 antibody that specifically binds to TNF- α . Infliximab blocks the interaction of TNF- α with TNF- α receptor 1 (TNFR1) and TNFR2. Infliximab is used in the study of autoimmunity, chronic inflammatory diseases, and diabetic neuropathy.

Product parameters

Alternative Names	TA-650, Remicade
Target Accession	P01375
Target	TNFSF2 / TNF α
CAS number	170277-31-3
Molecular Weight	145.98 kDa
Host	CHO
Reactivity	Human, Gorilla
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	Immobilized human TNF α , Fc Tag at 2 ug/mL can bind Anti-TNFSF2/TNF α Antibody (Infliximab), EC50=0.03538 ug/mL.
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 μ M filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

Note

1. This product is for scientific research use only.



APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

